TFS Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

TFS Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-22,599	Closed	-$886K	–	842
2017 Q1	$886K	Buy	+22,599	New	+$720K	0.29%	113
2016 Q3	–	Sell	-27,071	Closed	-$639K	–	1094
2016 Q2	$639K	Buy	27,071 +2,834	+12%	+$70K	0.12%	311
2016 Q1	$494K	Buy	+24,237	New	+$769K	0.07%	448
2015 Q1	–	Sell	-50,016	Closed	-$1.42M	–	1206
2014 Q4	$1.42M	Buy	50,016 +38,784	+345%	+$1.08M	0.14%	223
2014 Q3	$284K	Sell	11,232 -65,839	-85%	-$1.73M	0.02%	762
2014 Q2	$2.25M	Buy	77,071 +35,485	+85%	+$859K	0.18%	158
2014 Q1	$1.08M	Buy	41,586 +7,117	+21%	+$190K	0.07%	423
2013 Q4	$888K	Buy	34,469 +1,440	+4%	+$35K	0.04%	593
2013 Q3	$884K	Buy	33,029 +23,943	+264%	+$570K	0.04%	628
2013 Q2	$223K	Buy	+9,086	New	+$181K	0.01%	1281

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TFS Capital's PTLA Position: Q2 2017 in Review

TFS Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 22,599 shares — an estimated $886K sold.

TFS Capital first reported a position in PTLA in Q2 2013 and held it in 10 quarters. The position peaked at $2.25M in Q2 2014. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

TFS Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
TFS Capital sold 22,599 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $886K.
TFS Capital first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
TFS Capital's Portola Pharmaceuticals, Inc. position peaked at $2.25M in Q2 2014.
206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.